EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Targeting breast cancer resistance protein (BCRP/ABCG2) in cancer

Rouan Chen, Yue Yu, Ruixin Liu, Qian Chen

Translational Cancer Research · 2024-11 · 13 (11) · 6550-6564

DOI: 10.21037/tcr-24-1129 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Translational Cancer Research, 2024-11. Verfasst von Rouan Chen und 3 weiteren Autor:innen. Beteiligte Einrichtung: Medical College of Ophthalmology and Optometry, Shandong University of Traditional Chinese Medicine, Jinan, China. Die Arbeit wurde bisher 27-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Breast cancer is one of the most common cancers among women. Nowadays postoperative adjuvant chemotherapy is the mainstay for clinical treatment of breast cancer. However, the emergence of multidrug resistance (MDR) in breast cancer has become a main reason for the failure of clinical chemotherapy. Multiple studies have demonstrated that the formation of MDR in breast cancer is combined with ATP-binding transporters, which are the proteins that can lead to the drug resistance by pumping out chemotherapeutic drugs to reduce their intracellular accumulation. This kind of protein mainly includes P-glycoprotein (Pgp, ABCB1, MDR1), multidrug resistance-associated protein (MRP-1, ABCC1) and breast cancer resistance protein (BCRP, ABCG2). The former two transporters have been investigated deeply and widely, while the molecular mechanism of BCRP regulation of breast cancer drug resistance has relatively not much been explored in the area of breast cancer. How to design a novel, effective and non-toxic BCRP inhibitor to reverse the MDR of breast cancer, and boost the success rate of chemotherapy is a serious challenge at present. A detailed overview of the molecular role of BCRP-mediated breast cancer MDR and its inhibitors reported in recent years is provided in this article. The expectation is to provide ideas for clinically addressing MDR in breast cancer, and further guide the direction for the development of new anti-breast cancer drugs and reversal of breast cancer MDR drugs.

Schlagwörter

Stichwörter der Autor:innen

Breast cancerbreast cancer resistance protein (BCRP)multidrug resistance (MDR)transcriptional activation

Autor:innen und Institutionen

  • Medical College of Ophthalmology and Optometry, Shandong University of Traditional Chinese Medicine, Jinan, China.
  • College of Traditional Chinese Medicine, Shandong University of Traditional Chinese Medicine, Jinan, China.
  • Department of Pathology, Medical College, Shandong University of Traditional Chinese Medicine, Jinan, China.

Zitieren

APA

Chen, R., Yu, Y., Liu, R., & Chen, Q. (2024). Targeting breast cancer resistance protein (BCRP/ABCG2) in cancer. Translational Cancer Research, 13(11), 6550-6564. https://doi.org/10.21037/tcr-24-1129

Vancouver

Chen R, Yu Y, Liu R, Chen Q. Targeting breast cancer resistance protein (BCRP/ABCG2) in cancer. Translational Cancer Research. 2024;13(11):6550-6564. doi:10.21037/tcr-24-1129

BibTeX
@article{Chen2024,
  author = {Chen, Rouan and Yu, Yue and Liu, Ruixin and Chen, Qian},
  title = {Targeting breast cancer resistance protein (BCRP/ABCG2) in cancer},
  journal = {Translational Cancer Research},
  year = {2024},
  volume = {13},
  number = {11},
  pages = {6550--6564},
  doi = {10.21037/tcr-24-1129}
}
Kostenlos starten →